TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea

Executive Summary

• TempraMed Technologies announced a new commercial order and an expanded distribution agreement with Mavericks Co. Ltd (“Mavens”) in South Korea.
• The partnership leverages a recently granted South Korean patent covering TempraMed’s thermal‑insulation technology, enhancing market penetration for temperature‑sensitive injectable therapies.
• Expansion builds on prior agreements in Turkey, Israel, and Europe, signaling accelerated global growth for the company’s VIVI Cap Smart device and related product line.

Key Details

• Partner: Mavericks Co. Ltd (“Mavens”), a South Korea–based healthcare distribution company.
• Agreement Scope: Extension of existing distribution relationship to cover additional products and larger order volumes across pharmacies, hospitals, clinics, and patient communities in South Korea.
• Patent Protection: Recent grant of a South Korean patent protecting TempraMed’s proprietary thermal‑insulation technology.
• Market Context: South Korea’s injectable therapy market is among the fastest‑growing in Asia; the diabetes drug segment alone is valued at ~US $1 billion and expected to expand with rising prevalence.
• Product Focus: Temperature‑sensitive medications such as insulin, GLP‑1 receptor agonists, biologics, and emergency injectables; TempraMed’s VIVI Cap Smart device highlighted as a key offering.
• Strategic Rationale: Strengthen foothold in South Korea to accelerate market penetration, support chronic‑condition patients, and capitalize on growing demand for reliable passive thermal protection solutions.
• Previous Expansion: Prior distribution agreements established in Turkey, Israel, and Europe, indicating a broader global rollout strategy.

Notable Quotes

• “Our ongoing partnership with TempraMed has demonstrated the importance of practical, everyday solutions for patients using injectable medications,” – Chang Gyu An, CEO, Mavens.
• “This expanded partnership comes at a pivotal time for South Korea… we are better positioned than ever to ensure that patients and healthcare providers have access to reliable temperature‑protection solutions,” – Ron Nagar, CEO, TempraMed.